APA (7th ed.) Citation

MS, L., BY, R., CH, H., K, N., S, S., W, V., . . . KH, L. (2020). Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): An open-label, multicentre, phase 1b study. The Lancet. Oncology, 21(6), 808. https://doi.org/10.1016/S1470-2045(20)30156-X

Chicago Style (17th ed.) Citation

MS, Lee, et al. "Atezolizumab with or Without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-label, Multicentre, Phase 1b Study." The Lancet. Oncology 21, no. 6 (2020): 808. https://doi.org/10.1016/S1470-2045(20)30156-X.

MLA (9th ed.) Citation

MS, Lee, et al. "Atezolizumab with or Without Bevacizumab in Unresectable Hepatocellular Carcinoma (GO30140): An Open-label, Multicentre, Phase 1b Study." The Lancet. Oncology, vol. 21, no. 6, 2020, p. 808, https://doi.org/10.1016/S1470-2045(20)30156-X.